Frontiers in Pharmacology (Jan 2022)

Research Progress on Leucine-Rich Alpha-2 Glycoprotein 1: A Review

  • Yonghui Zou,
  • Yonghui Zou,
  • Yi Xu,
  • Yi Xu,
  • Xiaofeng Chen,
  • Xiaofeng Chen,
  • Yaoqi Wu,
  • Yaoqi Wu,
  • Longsheng Fu,
  • Yanni Lv

DOI
https://doi.org/10.3389/fphar.2021.809225
Journal volume & issue
Vol. 12

Abstract

Read online

Leucine-rich alpha⁃2 glycoprotein 1 (LRG1) is an important member of the leucine-rich repetitive sequence protein family. LRG1 was mainly involved in normal physiological activities of the nervous system, such as synapse formation, synapse growth, the development of nerve processes, neurotransmitter transfer and release, and cell adhesion molecules or ligand-binding proteins. Also, LRG1 affected the development of respiratory diseases, hematological diseases, endocrine diseases, tumor diseases, eye diseases, cardiovascular diseases, rheumatic immune diseases, infectious diseases, etc. LRG1 was a newly discovered important upstream signaling molecule of transforming growth factor⁃β (TGF⁃β) that affected various pathological processes through the TGF⁃β signaling pathway. However, research on LRG1 and its involvement in the occurrence and development of diseases was still in its infancy and the current studies were mainly focused on proteomic detection and basic animal experimental reports. We could reasonably predict that LRG1 might act as a new direction and strategy for the treatment of many diseases.

Keywords